Remove 2024 Remove Heart attacks Remove Strokes
article thumbnail

Chelation Therapy Does Not Improve Outcomes after Heart Attack

DAIC

The TACT2 study was designed to replicate the results of a previous trial, TACT , which reported in 2012 that chelation reduced subsequent cardiovascular events after a heart attack. and Canadian patients with diabetes and a history of heart attack,” said Gervasio A. and Canada.

article thumbnail

No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1, A Building Block of HDL Cholesterol

DAIC

milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at the American College of Cardiology ’s Annual Scientific Session.

article thumbnail

Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1

DAIC

The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at ACC.24, 24, the American College of Cardiology Annual Annual Scientific Session.

article thumbnail

Stroke or stroke plus neck artery tear almost doubles risk of heart attack within a year, finds research

Medical Xpress - Cardiology

Heart attack risk almost doubles in the first year after a stroke or when combined with a tear in a neck artery wall; however, a tear without a stroke does not seem to raise heart attack risk, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2024.

article thumbnail

Anthos Presents New Analysis from P2 AZALEA-TIMI 71 Study

DAIC

tim.hodson Mon, 11/18/2024 - 10:55 Nov. 4] "Many patients taking antiplatelet therapy are simply not prescribed anticoagulants because of the fear of bleeding, leaving them without protection from the risk of stroke,” said Dan Bloomfield, MD, chief medical officer of Anthos Therapeutics. incidence rate for rivaroxaban to a 3.5%

article thumbnail

International Stroke Conference Researcher Finds AI-based System Helped Guide Treatment, Lowered Stroke Recurrence

DAIC

Image courtesy: Getty Images christine.book Thu, 02/08/2024 - 15:53 February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association ’s International Stroke Conference , ISC 2024 , shed light on the use of artificial intelligence ( AI ) to help guide treatment decisions for stroke patients.

Research 105
article thumbnail

Questioning Beta-Blocker Interruption After Heart Attack

CardiacWire

Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heart attacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect. vs. 2.5%), and stroke (1% vs. 1%).